1206PD - Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

Date 09 October 2016
Event ESMO 2016 Congress
Session NSCLC, metastatic
Topics Cytotoxic agents
Non-small-cell lung cancer
Therapy
Biological therapy
Presenter Alice Shaw
Citation Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383
Authors A. Shaw1, G.J. Riley2, Y. Bang3, D. Kim4, D.R. Camidge5, M. Varella-Garcia5, A.J. Lafrate1, G. Shapiro6, M. Winter7, T. Usari8, S.C. Wang7, K. Wilner7, J.W. Clark1, S.I. Ou9
  • 1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
  • 2Memorial Sloan-kettering Cancer Center, Memorial Sloan-Kettering Cancer Center, New York/US
  • 3Department Of Internal Medicine, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
  • 4Department Of Internal Medicine, Seoul National University Hospital, Seoul/KR
  • 5Cancer Center, University of Colorado, Aurora/US
  • 6Early Drug Development Centre, Dana-Farber Cancer Institute, Boston/US
  • 7Oncology, Pfizer, La Jolla/US
  • 8Oncology, Pfizer, Milano/IT
  • 9University Of California At Irvine, University of California at Irvine, Irvine/US

Abstract

Background

In the phase I study PROFILE 1001, crizotinib showed marked antitumor activity in advanced ROS1-rearranged NSCLC (Shaw, N Engl J Med 2014). We present updated data for 53 patients (pts) with ROS1-rearranged NSCLC from this ongoing study (NCT00585195).

Methods

ROS1 status was determined by break-apart FISH test or RT-PCR test. All pts received crizotinib at a starting dose of 250 mg orally twice daily.

Results

Fifty-three pts enrolled and were treated with crizotinib for a median treatment duration of 23.2 months. All were included in the efficacy and safety analyses. At data cutoff (November 30, 2014), treatment was ongoing in 25 pts (47%). The median age of pts was 55 years, 57% were female, and 57% and 40% were white and Asian, respectively; all were never or former smokers. The objective response rate (ORR) was 70% (95% CI: 56, 82), which included five complete responses and 32 partial responses; 11 pts had stable disease. By independent radiology review (n = 50), ORR was 66% (95% CI: 51, 79). Responses were durable (median duration of response not reached [NR]; 95% CI: 15.2, NR). ORR was consistent across baseline and disease characteristics, and appeared independent of the percentage of ROS1-rearranged cells. Median progression-free survival was 19.3 months (95% CI: 14.8, NR). At a median follow-up of 25.4 months, median overall survival was NR; the probabilities of survival at 6 and 12 months were 91% (95% CI: 79, 96) and 79% (95% CI: 65, 88), respectively. The safety profile was similar to that of crizotinib in pts with ALK-positive NSCLC. The most common treatment-related adverse events (TRAEs) were vision disorder (85%), nausea (49%), edema (45%), diarrhea (42%), and vomiting (38%), mainly grade 1 or 2 in severity. The most common grade 3 TRAEs were hypophosphatemia (13%), neutropenia (9%), and elevated transaminases (4%), and there were no grade 4 TRAEs. Of 16 deaths on study, none were attributed to crizotinib.

Conclusions

These updated data confirm the clinically meaningful benefit and safety of crizotinib in pts with advanced ROS1-rearranged NSCLC.

Clinical trial identification

Clinicaltrials.gov: NCT00585195

Legal entity responsible for the study

N/A

Funding

Pfizer

Disclosure

Y-J. Bang: Research funding from Pfizer to their institution. D.R. Camidge: Honararia from Pfizer. M. Winter, T. Usari, S.C. Wang, K. Wilner: Pfizer employee. All other authors have declared no conflicts of interest.